Simply sign up for a free PR Canna Zine membership, and post your press release. Its as easy as that!
From that point forth your press release will be published alongside the daily CannaZine press output, which is indexed by Google News many times a day.
http://www.provigil-rx.info: The pharmaceutical industry is no stranger to dirty tricks and shady dealings in a bid to keep its customers coming back time and again. Although they would prefer to call it “just doing business”.
Indeed shifting patients from a soon-to-go-off-patent blockbuster, to its tweaked successor, whilst being frowned upon by the FDA, is old hat in the pharma biz.
Ever since drugmakers figured out that adding a time-release coating or other slight improvement could earn it a new round of patent protection, they've been developing strategies for competing against their own meds.
Raising the price of the old version to get patients to switch to the new brand, hoping they'll stick when the old one goes generic? Done. Touting the slight improvement as if it's a major advance? Also done.
http://www.provigil-rx.info : Although generic modafinil (Provigil) has been available for some time from one or two pharmacies under the brand name 'Modalert', the rest of the industry is now up in arms over what its calling the “Cephalon conspiracy”, in which the US drug manufacturer is accused of striking a $200 million deal to keep generic drug makers away from Provigil.
So the story goes, Cephalon conspired with other drug makers to delay generic competition for its blockbuster drug Provigil, pharmacy chains say in a federal antitrust class action.
Rite-Aid, Eckerd, Brooks and CVS Caremark sued Cephalon and generic drug manufacturers Mylan, Barr, Teva, and Ranbaxy Pharmaceuticals, claiming Cephalon bought more time for its "wakefulness promoting agent" by paying more than $200 million to generic manufacturers in four patent settlements.
